PROTAC EZH2 Degrader-2
Product Specifications
UNSPSC Description
PROTAC EZH2 Degrader-2 (compound E-3P-MDM2), an EZH2 inhibitor, is a PROTAC composed of Tazemetostat (EPZ6438) and an E3 ligase system ligand. PROTAC EZH2 Degrader-2 degrades EZH2 in SU-DHL-6 cells in a dose-dependent manner, inhibits the expression of H3K27me3, and simultaneously degrades EED and SUZ12 proteins without affecting their mRNA levels. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity[1].
Target Antigen
Histone Methyltransferase; PROTACs
Type
Reference compound
Related Pathways
Epigenetics;PROTAC
Applications
Cancer-programmed cell death
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/protac-ezh2-degrader-2.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(C)=C(CNC(C2=CC(C3=CC=C(CN4CCN(C(C5=CN(CCOCCOCCOCCNC(CN6CCN(C(N7C(C8=CC=C(OC)C=C8OC(C)C)=N[C@H](C9=CC=C(Cl)C=C9)[C@@H]7C%10=CC=C(Cl)C=C%10)=O)CC6=O)=O)N=N5)=O)CC4)C=C3)=CC(N(C%11CCOCC%11)CC)=C2C)=O)C(N1)=O
Molecular Weight
1463.55
References & Citations
[1]Xie H et al. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma. Bioorg Chem. 2023 Nov;140:106762.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-157164/PROTAC-EZH2-Degrader-2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-157164/PROTAC-EZH2-Degrader-2-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CSB-EP751251HU-01 20 µg
Recombinant Human Immunoglobulin-like domain-containing receptor 2 (ILDR2), partial
Ask
View Details 
CSB-EP751251HU-02 100 µg
Recombinant Human Immunoglobulin-like domain-containing receptor 2 (ILDR2), partial
Ask
View Details CSB-EP751251HU-03 1 mg
Recombinant Human Immunoglobulin-like domain-containing receptor 2 (ILDR2), partial
Ask
View Details 